mRNA-based drug company launches with $82 million
Drug Discovery World
JUNE 27, 2024
Genomic medicine developer Exsilio Therapeutics has emerged from stealth with $82 million in Series A financing. The funding was co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, JP Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight.
Let's personalize your content